InterMune Soars on FDA Advisory Panel Backing for Lung Disease Treatment (ITMN)
Wednesday, March 10, 2010 - 11:48
Written on Wed, 03/10/2010 - 11:48am
By Chip Brian

3/10/2010-Shares of InterMune (NASDAQ:ITMN) are trading 65.5% higher to $38.55 Wednesday after the maker of pirfenidone for the treatment of idiopathic pulmonary fibrosis, a deadly lung disease that afflicts about 100,000 Americans, won a U.S. panel's backing to introduce the medicine.
Investor confidence could be based on the rule of thumb that the Food and Drug Administration usually follows the recommendations of its advisory panels.
In addition, Thomas Weisel Partners raised the company's price target from $26 to $55.
SmarTrend is bullish on shares of ITMN and our subscribers were alerted to Buy on March 05, 2010 at $23.83. The stock has risen 62.4% since the alert was issued.

Keywords: intermune fda advisory panel Stock treatment smartrend

Ticker(s): ITMN

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.